Table 1. Risk of late Grade 3 or greater bladder toxicity in patients treated for bladder cancer in selected series not included in Marks et al. (1).

Investigator	Patients (n)	Simulation imaging	Total dose (Gy)	Whole-bladder dose (Gy)	Partial-bladder dose (Gy)	Fraction size (Gy)	Fractions (n)	EQD2 (Gy)	Late Grade ≥3 toxicity (%)
Duncan et al. (9)*	889	2D	55–57.5	55–57.5		2.75–2.88	20	60.2–63.8	17
Moonen et al. (10)*	15	3D	66	66		2	Last 8 b.i.d.	66	0
	25		66	66		2	Last 13 b.i.d.		31
Rödel et al.(11)*	186*	2D	45–69.4	45–69.4		1.8–2	25–33	45–69.4	4y
Scholten et al. (12)*	123	2D	36	36		6	6 (2x/wk)	54	0
Mameghan et al. (13)*	330	2D	65	45–65		1.8–2.5	25–30	43.9– 69	2y
Perdona et al. (14)*‡	121	3D	65	65		1.8	35	63.4	4y
Mangar et al. (15)* (CD)	154	3D	60–64	60–64	—	2	30–32	60–64	42
	75		60–64	48–52	12	2	24–26	52/60–64	23
Cowan et al. (16)*§	25	3D	52.5	52		2.63	20	56.3	4
PB	22		57.5		57.5	2.88	20	56.3–63.8	18
PB	16		55		55	3.44	16	57.1–64.9	6
Yavuz et al. (17) (CD)	87	3D	45/67.5	45	22.5	1.8/1.5 CB	35	43.9–65	1
Pos et al. (18) (CD)	47	3D	55 40	55 40	— 15	2/2.75 CB	20	40/55	9
Shipley et al. (19, 27) (CD)	157	2D	64–65	52–55	12–15	1.8/1.5–1.8	36–42	60.9–62.2	6

Abbreviations: EQD2 =equivalent dose in 2-Gy fractions, assuming α/β =6; 2D = two-dimensional conventional simulation; 3D =CT-based three-dimensional planning; b.i.d. = twice daily; PB = all treatment fields included only part of bladder, as determined by primary tumor site using CT-based planning; CD = first phase included whole bladder followed by cone down to partial bladder with CT-based planning; CB = concomitant boost; CT = computed tomography.

^*Treatment to the whole bladder as localized with contrast or CT.

^†Concurrent with chemotherapy.

^‡Bladder in treatment fields; cone down from pelvic fields at median dose of 45 Gy.

^§Grade 2 or greater toxicity reported.